Akari Therapeutics, Plc (AKTX)
| Market Cap | 15.80M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -15.77M |
| Shares Out | 35.74M |
| EPS (ttm) | -0.57 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 164,052 |
| Open | 0.4500 |
| Previous Close | 0.4500 |
| Day's Range | 0.4164 - 0.4721 |
| 52-Week Range | 0.4164 - 1.7300 |
| Beta | 0.25 |
| Analysts | Strong Buy |
| Price Target | 3.30 (+646.44%) |
| Earnings Date | Nov 13, 2025 |
About AKTX
Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads include PH5, which inhibits DNA mismatch repair (MMR... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for AKTX stock is "Strong Buy." The 12-month stock price target is $3.3, which is an increase of 646.44% from the latest price.
News
Akari Therapeutics, Plc (AKTX) Shareholder/Analyst Call Transcript
Akari Therapeutics, Plc ( AKTX) Shareholder/Analyst Call November 18, 2025 11:00 AM EST Company Participants Abizer Gaslightwala - CEO, President & Director Satyajit Mitra - Executive Director & Head...
Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer
More than 20 years of financial and operational leadership in biopharma, including $170M+ in capital raised, global commercialization experience, and a proven track record scaling companies from precl...
Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors
Data presented at the 40 th Annual Society for Immunotherapy of Cancer (SITC) Meeting The spliceosome targeting payload, PH1, demonstrates the ability to induce both cancer cell cytotoxicity and activ...
Akari Therapeutics' Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available
Data to be presented at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting on November 7th and 9th Data to be presented at the 40th Annual Society for Immunotherapy of Cancer (SITC) Me...
Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP
Dr. Hurvitz is an international expert in oncology and a recognized clinical research leader with extensive experience leading clinical trials spanning all phases Dr. Hurvitz is an international exper...
Akari Therapeutics Announces Launch of CEO Corner Platform
CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides interested parties with the ability to ask questions and submit topics for fut...
Akari Therapeutics Announces $2.5 Million Registered Direct Offering
BOSTON and LONDON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (the “Company”), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs),...
Akari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1
BOSTON and LONDON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced...
Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
BOSTON and LONDON, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced...
Akari Therapeutics' Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1
Data highlights ability of Akari's ADC payload, PH1, to suppress the levels of the AR-V7 receptor that is responsible for driving hormone refractory prostate cancer progression
Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer
BOSTON and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announce...
Akari Therapeutics, Plc (AKTX) Discusses At Virtual Investor Closing Bell Series Call (Transcript)
Akari Therapeutics, Plc (NASDAQ:AKTX) Discusses at Virtual Investor Closing Bell Series Call Company Participants Abizer Gaslightwala - CEO, President & Director Conference Call Participants Jenene T...
Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
BOSTON and LONDON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announce...
Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series
Live moderated webcast on Thursday, September 4 th at 4:00 PM ET Access the event here BOSTON and LONDON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotech...
Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
BOSTON and LONDON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads for ...
Akari Therapeutics Releases Virtual Investor “What This Means” Segment
Abizer Gaslightwala, President and CEO of Akari Therapeutics discussed Akari's commitment to continued research to better understand the multiple effects of its novel spliceosome modulator, PH1 Abizer...
Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers
PH1 modulates RNA splicing, causing cancer cell death while activating the immune system to attack cancer throughout the body
Akari Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference
BOSTON and LONDON, July 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) ...
Akari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its Recently Granted India Patent
Access the “What This Means” segment here BOSTON and LONDON, June 25, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncolog...
Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India
Differentiated PH1 payload is a spliceosome inhibitor designed to inhibit RNA splicing, leading to cancer cell death and activation of immune system through multiple mechanisms
Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology
Well-established industry leader whose oncology expertise and transactions record has led to multiple approved therapeutic products and advanced clinical product candidates Well-established industry l...
Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
BOSTON and LONDON, May 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced ...
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rache...
Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Advancing development of novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads to treat multiple cancer tumors
Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology
Global expertise in establishing and executing transformative transactions which have led to multiple approved therapeutic products